Table 4

Most common treatment-related adverse events in patients treated with indoximod+pembrolizumab (≥10% of patients, N=114)

Adverse eventAll grades, n (%)Grade 3, n (%)
Fatigue71 (62.3)2 (1.8)
Rash46 (40.4)5 (4.3)
Pruritus40 (35.1)0
Nausea32 (28.1)1 (0.9)
Diarrhea26 (22.8)0
Arthralgia25 (21.9)1 (0.9)
Decreased appetite21 (18.4)0
Headache21 (18.4)0
Constipation19 (16.7)0
Hypothyroidism15 (13.2)0
Cough13 (11.4)1 (0.9)
Vomiting12 (10.5)0